Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio
Company Announcements

Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio

Roivant Sciences ( (ROIV) ) has shared an update.

Organon has successfully acquired Dermavant Sciences, expanding its dermatology portfolio with the innovative VTAMA® cream for treating plaque psoriasis. This strategic move enhances Organon’s capabilities in providing nonbiologic, non-steroidal topical treatments, potentially addressing atopic dermatitis in the future. With this acquisition, Organon aims to leverage its global reach to maximize VTAMA’s impact on patients worldwide, while continuing to advance its mission to improve healthcare solutions.

For detailed information about ROIV stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyOrganon completes acquisition of Dermavant
TheFlyJPMorgan SMid cap biotech analyst holds an analyst/industry conference call
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App